Press Releases

Date Title and Summary Additional Formats
Toggle Summary Potent in vitro Activity of SCYNEXIS' SCY-078 Against Multidrug-Resistant Fungal Pathogen Candida auris Further Confirmed in an in vitro Study Conducted by the Centers for Disease Control and Prevention (CDC)
SCY-078 may provide a therapeutic option for this emerging pathogen classified as a serious global health threat by the CDC Multiple studies confirm SCY-078's broad spectrum of activity against Candida species, including resistant strains JERSEY CITY, N.J., May 11, 2017 (GLOBE NEWSWIRE) -- SCYNEXIS
View HTML
Toggle Summary SCYNEXIS Reports First Quarter 2017 Financial Results and Provides Update on IV Formulation Development Status
JERSEY CITY, N.J., May 08, 2017 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company delivering innovative anti-infective therapies for difficult-to-treat and often life-threatening infections, today reported financial results for the quarter ended March 31, 2017, and provided
View HTML
Toggle Summary Eight Data Presentations at ECCMID Showcase the Broad Applicability of SCYNEXIS' Lead Anti-infective Candidate SCY-078
Presentations support SCY-078's potential as a novel treatment for  Candida infections including multidrug-resistant strains Favorable safety profile of SCY-078 supported by clinical studies presented Conference call to review ECCMID SCY-078 data to be held April 25 at 4:05 p.m.
View HTML
Toggle Summary SCYNEXIS to Host a Conference Call to Discuss Lead Anti-Infective Candidate SCY-078 Data Presented at 27th ECCMID
JERSEY CITY, N.J., April 21, 2017 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company delivering innovative anti-infective therapies for difficult-to-treat and often life-threatening infections, today announced that it will hold a conference call at 4:05 p.m.
View HTML
Toggle Summary SCYNEXIS to Present SCY-078 Data on Novel Lead Anti-infective Candidate at 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
Oral presentation of Phase 2 study discusses oral SCY-078 in patients with invasive candidiasis Potent in vitro activity of SCY-078 against multidrug-resistant fungal pathogen Candida auris In vitro synergy of SCY-078 in combination with other antifungals against Aspergillus Additional posters
View HTML
Toggle Summary SCYNEXIS, Inc. to Present at the 16th Annual Needham Healthcare Conference
JERSEY CITY, N.J., March 29, 2017 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a drug development company committed to the development and commercialization of novel anti-infectives to address significant unmet therapeutic needs, today announced that the Company will present at the 16 th
View HTML
Toggle Summary SCYNEXIS Reports Full Year 2016 Financial Results and Provides Company Update
JERSEY CITY, N.J., March 13, 2017 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a drug development company committed to the development and commercialization of novel anti-infectives to address significant unmet therapeutic needs, today reported financial results for the year ended December 31,
View HTML
Toggle Summary SCYNEXIS, Inc. to Present at the 29th Annual ROTH Conference
JERSEY CITY, N.J., March 07, 2017 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (NASDAQ:SCYX) today announced that the Company will present at the 29 th Annual ROTH Conference at the Ritz Carlton Laguna Niguel in Dana Point on Tuesday, March 14, 2017 at 5:30 p.m. PT.
View HTML
Toggle Summary SCYNEXIS delays initiation of new clinical studies using the IV formulation of SCY-078 at FDA's request
Ongoing and future clinical development using the oral formulation of SCY-078 are unaffected
View HTML
Toggle Summary SCYNEXIS, Inc. to Participate in Upcoming Investor Conferences
JERSEY CITY, N.J., Jan. 31, 2017 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (NASDAQ:SCYX) today announced that the Company will participate in the following upcoming investor conferences: Canaccord Genuity Rare Disease Conference at the InterContinental New York Barclay Hotel in
View HTML